Key result
Updated ESC guidelines introduce SCORE2 and SCORE2-OP to estimate 10-year CVD risk across age groups.
Why the study?
Many patients still do not receive needed care and control of CV risk factors remains suboptimal across Europe, while evidence for primary prevention in low-to-moderate-risk and multimorbid older patients remains limited.
Answers are grounded in this paper and cite their sources.
Reviews the 2021 European cardiovascular prevention guidelines and risk estimation models, highlighting evidence gaps in managing older and multimorbid populations.
This year, the European Society of Cardiology (ESC) presented its 2021 guidelines of cardiovascular (CV) prevention in clinical practice 5 years after the last update.1 ‘Guidelines’ are defined as information intended to advise medical staff on how something should be done or what something should be done.2 Several studies have shown that the implementation of guidelines was associated with an improvement in clinical outcomes and have demonstrated that the guidelinedriven medicine is also costreducing and increasing physician satisfaction.3 Unfortunately, still a high number of patients do not receive the quality of care they need and the control of CV risk factors remains suboptimal across several European countries.4 Recently, patientcentred care has been considered to better understand patient's perspectives when recommendations are formulated5 and to involve patients in evidencebased decisionmaking and in efficient care.6 The new 2021 guidelines on CV prevention1 described in an exhaustive manner and with a holistic approach how to intervene in clinical practice, both at the individual and at the population levels, to reduce the burden of atherosclerotic cardiovascular diseases (ASCVDs). Recommendations are classified according to the class of recommendation, being class I as ‘recommended or indicated’, class IIa as ‘should be considered’, class IIb as ‘may be considered’ and class III as ‘not recommended’. Level of evidence (levels A, B and C) depends on the proportion of different data derivation, being level A as data derived from multiple randomized clinical trials or metaanalyses, level B as data derived from a single randomized clinical trial or large nonrandomized studies and level C as data derived from the opinion of the experts and/or small studies, retrospective studies or registries. At the individual level, novel recommendations aim to estimate the 10year risk of CV events for apparently healthy individuals according to three age groups (<50 years, between 50 and 69 years, and ≥70 years). Compared with 2016 ESC prevention guidelines where the Systemic Coronary Risk Estimation (SCORE) predicted a 10year risk of CV death in an overall range of age, the SCORE2 and SCORE2OP recommended in the 2021 guidelines estimate an individual's 10year risk of fatal and nonfatal CVD events with an adaptation of the predictive model according to the three age categories. Of note, patients with established ASCVD and/or diabetes, and/or moderatetosevere renal disease and/or genetic/ rarer lipid or BP disorders are considered to be at high or very high CVD risk, and they need treatment intensification (class of recommendation I and level of evidence B), with a stronger level of evidence (in general, level of evidence A given the large trials). Those veryhighrisk patients were included preferably in clinical trials because their baseline features were more likely to increase the incidence of CV events and therefore the statistical power to show a superiority of an intervention over the study duration. In contrast, patients classified as low or moderate risk require lifestyle intervention in priority and the level of evidence to initiate pharmacological therapies remains weaker given the lack of dedicated trials. For the first time, recommendations for older patients are discussed with more details in the guidelines. The estimated CV risk with these models gives in general highrisk values even in apparently healthy people ≥70 years old. However, older individuals could also have multimorbidity (>3 chronic conditions) and polypharmacy and be affected more by nonCV diseases (eg cancer or dementia). This point has been considered, as, for example, treatment with statin at a low dose is recommended in people ≥70 years old who have a significant renal impairment and/or the potential for drug interactions (class of recommendation I and level of evidence C). In general, multimorbid subjects have been excluded from clinical trials for many reasons (eg competitive risks, inability to followup, lack of adherence, side effects and inability to give consent), and thus, the level of evidence is still suboptimal in this population for treatment indication in primary prevention. The guideline acknowledges the lack of clear data evaluating the efficacy of statin in primary prevention in older patients. More definitive answers are
No takes yet. Share an insight, caveat, or question.
Gencer et al. (2022) conducted an editorial in Atherosclerotic cardiovascular disease (ASCVD) prevention. 2021 ESC guidelines on cardiovascular prevention (SCORE2 and SCORE2-OP) vs. 2016 ESC prevention guidelines (SCORE) was evaluated. The 2021 ESC guidelines introduce SCORE2 and SCORE2-OP to estimate 10-year fatal and non-fatal CVD risk across three age groups (<50, 50-69, and ≥70 years).
Synapse has enriched 10 related papers. Consider them for comparative context: